The estimated Net Worth of John D. Manders is at least $224 millier dollars as of 11 August 2021. Mr Manders owns over 2,608 units of Surmodics stock worth over $224,239 and over the last 6 years he sold SRDX stock worth over $0.
Mr has made over 1 trades of the Surmodics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 2,608 units of SRDX stock worth $59,854 on 11 August 2021.
The largest trade he's ever made was exercising 2,608 units of Surmodics stock on 11 August 2021 worth over $59,854. On average, Mr trades about 145 units every 0 days since 2018. As of 11 August 2021 he still owns at least 5,716 units of Surmodics stock.
You can see the complete history of Mr Manders stock trades at the bottom of the page.
John D. Manders is the Corp. Controller & Principal Accounting Officer at Surmodics.
Mr Manders is 40, he's been the Corp. Controller & Principal Accounting Officer of Surmodics since . There are 20 older and no younger executives at Surmodics. The oldest executive at Surmodics, Inc. is David Dantzker, 76, who is the Independent Director.
John's mailing address filed with the SEC is 9924, West 74th Street, Eden Prairie, Hennepin County, Minnesota, 55344, United States of America.
Over the last 21 years, insiders at Surmodics have traded over $26,204,565 worth of Surmodics stock and bought 19,725 units worth $436,251 . The most active insiders traders include Jeffrey C Smith, Gary R Maharaj et Value Lp Starboard Value Gp.... On average, Surmodics executives and independent directors trade stock every 34 days with the average trade being worth of $415,014. The most recent stock trade was executed by Joseph J. Stich on 21 August 2024, trading 21,285 units of SRDX stock currently worth $706,662.
surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.
Surmodics executives and other stock owners filed with the SEC include: